ERBB2 and invasive breast carcinoma: To evaluate the transcriptomic and genomic changes during HER2 amplification in DCIS, we screened 25 HER2-positive invasive breast cancer patients by HER2 immunohistochemistry (IHC) and selected cases with a large DCIS components.